• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding

    12/2/25 9:15:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email

    Incyte (NASDAQ:INCY) today announced its partnership with world renowned supermodel and beauty entrepreneur Winnie Harlow — one of the most recognizable people living with vitiligo — to raise awareness of vitiligo through "The Power of Choice" campaign.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125041103/en/

    Winnie partners with Incyte to raise awareness of vitiligo

    Winnie partners with Incyte to raise awareness of vitiligo

    Vitiligo is a chronic autoimmune condition characterized by loss of pigment in the skin, resulting in white patches that can appear anywhere on the body. Affecting an estimated 1.9 to 2.8 million adults in the United States1, vitiligo can have a profound impact on how people feel about themselves and how they are perceived by others.2-4

    Winnie has lived with vitiligo for most of her life and faced related challenges, including hurtful comments and lack of understanding from others about the condition. As part of the partnership, Winnie steps into her past in two new videos, revisiting her childhood and sharing advice for her younger self and others on similar journeys.

    "Growing up with vitiligo, I often felt like I was the only person in the world like me," said Winnie Harlow. "Over time, I've learned that it isn't just about what you see on the skin — it's also about understanding vitiligo on a deeper level. I've partnered with Incyte to help other people with vitiligo feel seen, supported and empowered to explore options that are right for them. You only get one life in your skin, and you choose how you want to live it."

    In the videos, Winnie reflects on how misconceptions about vitiligo have shaped her experiences and identity. She also emphasizes the importance of people learning about the condition and engaging with healthcare professionals and choosing for themselves how they manage vitiligo. By connecting Winnie's past with her present, the campaign validates every experience and encourages people to choose their own paths.

    "People living with vitiligo are the experts of their own experiences. As a dermatologist, I recognize how important it is to listen to them and partner closely on a personalized approach built on their goals and choices," said Pearl E. Grimes, M.D., F.A.A.D., Director, Vitiligo and Pigmentation Institute of Southern California, and Immediate Past President of the Global Vitiligo Foundation. "Managing vitiligo is a lifelong process — and for those who choose to treat, progress can take time — but with knowledge, patience and support, people can feel more in control of their health."

    "Each person's journey with vitiligo is unique. We are honored to partner with Winnie to share and amplify her personal story as part of our commitment to highlighting the lived experiences of people with vitiligo," said Matteo Trotta, Executive Vice President, General Manager, U.S. Dermatology, Incyte. "We hope the campaign encourages people to learn more about the condition and their options in partnership with a dermatologist, whether it is treatment, care or simply understanding what's happening beneath the skin."

    To learn more about vitiligo and Winnie's journey, visit ThisIsVitiligo.com.

    Winnie Harlow has been compensated for her participation.

    About Winnie Harlow

    Winnie Harlow is a world-renowned supermodel and beauty entrepreneur, hailed by Vogue as "one of the most recognized faces on the international fashion scene." Winnie has maintained a successful career in the fashion world, recently walking runways for VETEMENTS and Marine Serre, sitting front row at Marc Jacobs, attending the CFDA Fashion Awards with Amazon Fashion, speaking for a panel at Vogue's Forces of Fashion in Germany, and continuing to cover international fashion magazines around the globe. Apart from the fashion world, Winnie has continued to grow her skincare business Cay Skin, which she founded in 2022 when she became one of only 12 women of color to receive funding in excess of $1 million as a founder, raising an impressive $4.1 million to launch the brand. Diagnosed with vitiligo at age 4, Winnie uses her platform to showcase the importance of diversity in the beauty community and open doors for broader representation. This past summer, she unveiled her Madame Tussauds wax figure on World Vitiligo Day — making history as the first person ever mapped in wax with vitiligo. In fall 2023, she returned to her native Canada, where she was honored to accept the United Nations Association in Canada's Global Citizen Award for her work shattering norms in the fashion industry and her profound advocacy for diversity and female empowerment. Furthering her philanthropy initiatives, last year she visited South Africa to present the Earthshot Prize to the Altyn Dala Conservation Initiative at the annual event that recognizes innovative solutions to environmental challenges.

    About Incyte Dermatology

    Incyte's science-first approach and expertise in immunology has formed the foundation of the company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.

    We strive to identify and develop therapies to modulate immune pathways driving uncontrolled inflammation to help restore normal immune function and bring the body closer to homeostasis. Specifically, our efforts in dermatology are focused on a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, hidradenitis suppurativa and prurigo nodularis.

    To learn more, visit the Dermatology section of Incyte.com.

    About Incyte

    A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

    For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

    Incyte Forward-Looking Statements

    Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the partnership between Incyte and Winnie Harlow, Incyte's goal of improving the lives of patients, and Incyte's dermatology program generally, contain predictions, estimates, and other forward-looking statements.

    These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and other regulatory agencies; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended September 30, 2025. We disclaim any intent or obligation to update these forward-looking statements.

    ____________________________

    1 Results were from a cross-sectional, population-based, participant self-reported and clinician adjudicated online survey conducted between December 2019 and March 2020.

    2 Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of vitiligo among adults in the United States. JAMA Dermatol. 2022;158(1):43-50.

    3 Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159-164.

    4 Bibeau K, Pandya AG, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1831-1844.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251125041103/en/

    Media

    [email protected]

    Investors

    [email protected]

    Get the next $INCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    2/5/2026$135.00Buy
    H.C. Wainwright
    1/20/2026$107.00Overweight → Equal Weight
    Wells Fargo
    12/8/2025$121.00Neutral → Outperform
    Mizuho
    11/3/2025$125.00Neutral → Buy
    Guggenheim
    10/8/2025Outperform → Perform
    Oppenheimer
    8/6/2025$89.00Equal Weight → Overweight
    Wells Fargo
    8/1/2025$90.00Overweight
    Barclays
    6/16/2025$107.00Hold → Buy
    Stifel
    More analyst ratings

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Incyte with a new price target

    H.C. Wainwright initiated coverage of Incyte with a rating of Buy and set a new price target of $135.00

    2/5/26 6:58:02 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Incyte from Overweight to Equal Weight and set a new price target of $107.00

    1/20/26 9:09:45 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte upgraded by Mizuho with a new price target

    Mizuho upgraded Incyte from Neutral to Outperform and set a new price target of $121.00

    12/8/25 8:14:28 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    SEC Filings

    View All

    SEC Form 10-K filed by Incyte Corp.

    10-K - INCYTE CORP (0000879169) (Filer)

    2/10/26 4:01:52 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INCYTE CORP (0000879169) (Filer)

    2/10/26 7:06:32 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by Incyte Corp.

    144 - INCYTE CORP (0000879169) (Subject)

    1/6/26 4:05:35 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

    Total revenue of $1.51 billion (+28% Y/Y) in the fourth quarter 2025 and $5.14 billion (+21% Y/Y) for the full year 2025 Total net product revenue of $1.22 billion (+20% Y/Y) in the fourth quarter 2025 and $4.35 billion (+20%) for the full year 2025, exceeding full year 2025 net product revenue guidance of $4.23 - $4.32 billion Provides full year 2026 total net product revenue guidance range of $4.77 - $4.94 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided full year 2026 financial guidance. "Our fourth quarter and full year 2025 result

    2/10/26 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

    Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in Europe Globally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3 The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplati

    1/30/26 9:29:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte to Report Fourth Quarter and Year-End 2025 Financial Results

    Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 10, 2026. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2025 Press Release: February 10, 2026 at 7:00 a.m. ET Q4 & YE 2025 Conference Call: February 10, 2026 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13758313 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in n

    1/27/26 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

    9/28/21 5:20:01 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

    9/23/21 5:11:12 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for OPZELURA issued to INCYTE CORP

    Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    9/22/21 11:16:23 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Head of Tech. Operations Morrissey Michael James covered exercise/tax liability with 185 shares, decreasing direct ownership by 0.54% to 34,065 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    2/4/26 4:07:23 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP, Head of Incyte Intl Heeson Lee covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.29% to 38,041 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    2/4/26 4:07:01 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by President, R&D Cagnoni Pablo J

    4 - INCYTE CORP (0000879169) (Issuer)

    1/21/26 4:06:47 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    View All

    Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel

    Incyte (NASDAQ:INCY) announces the appointment of Richard Hoffman as Executive Vice President and General Counsel effective today, December 1, 2025. In his new role, Mr. Hoffman will serve as a key member of the Executive Leadership Team and be responsible for the Company's legal and compliance teams. "Richard joins us with a distinguished background, including many years of experience as a partner at a premier law firm, and a proven track record advising biopharma companies on corporate governance, strategic transactions, intellectual property and litigation," said Bill Meury, President and Chief Executive Officer, Incyte. "He possesses exceptional legal acumen and sound judgment to help

    12/1/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

    Incyte (NASDAQ:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company's strategy and business development. "Dave possesses a unique combination of business acumen, scientific knowledge and deep industry experience. His extensive background in biopharma investing will bring a fresh perspective and a focused, judicious approach to corporate development," said Bill Meury, President and Chief Executive Officer, Incyte. "Dave will play a pivotal role in developing a coherent and e

    9/22/25 7:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

    Incyte (NASDAQ:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company's global human resources strategy including talent acquisition, organizational design and professional development. "Soni has extensive knowledge and experience in all aspects of human resources," said Bill Meury, President and Chief Executive Officer, Incyte. "She is a skilled professional and collaborative leader who will bring a strategic mindset and operational focus to the company. Soni will pla

    8/25/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Financials

    Live finance-specific insights

    View All

    Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

    Total revenue of $1.51 billion (+28% Y/Y) in the fourth quarter 2025 and $5.14 billion (+21% Y/Y) for the full year 2025 Total net product revenue of $1.22 billion (+20% Y/Y) in the fourth quarter 2025 and $4.35 billion (+20%) for the full year 2025, exceeding full year 2025 net product revenue guidance of $4.23 - $4.32 billion Provides full year 2026 total net product revenue guidance range of $4.77 - $4.94 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided full year 2026 financial guidance. "Our fourth quarter and full year 2025 result

    2/10/26 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte to Report Fourth Quarter and Year-End 2025 Financial Results

    Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 10, 2026. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2025 Press Release: February 10, 2026 at 7:00 a.m. ET Q4 & YE 2025 Conference Call: February 10, 2026 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13758313 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in n

    1/27/26 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

    Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi®) in patients with myelofibrosis (MF) harboring a CALR mutation (mutCALR) Results demonstrate a favorable safety profile for INCA033989 as a monotherapy and in combination with ruxolitinib – no dose limiting toxicities were reported and a maximum tolerated dose was not reached A reduction in peripheral blood mutCALR variant allele frequency (VAF) from baseline was observed in MF patients in the INCA033989 monotherapy arm with ≥1 post-baseline VAF measurement Exploratory analyses from the clinical studies of INCA

    12/7/25 9:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Incyte Corp.

    SC 13G - INCYTE CORP (0000879169) (Subject)

    10/17/24 9:39:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by Incyte Corp.

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    6/14/24 6:23:05 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    5/13/24 6:06:33 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care